NewsBenzingaPrelude Therapeutics: utile per azione del terzo trimestre pari a $(0,12), inferiore di $0,04 alle stime; ricavi per $5,647 milioni, sotto le stime di $29,000 milioni. Prelude Therapeutics: utile per azione del terzo trimestre pari a $(0,12), inferiore di $0,04 alle stime; ricavi per $5,647 milioni, sotto le stime di $29,000 milioni. Benzinga 2026.11.16 12:16 (GMT+0) Open on Benzinga Other news Paytaca: Backend Systems Attacked but User Funds and Private Keys Unaffected, Warns Against Interacting with Suspicious Orders ‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors Analysis: Bitcoin's 12% Weekly Drop and Break Below 200-Week Moving Average — All Three Similar Historical Cases Rose Three Months Later Can Colette Kress Fill Jensen Huang’s Shoes? Nvidia Posts $116 Billion Quarter, but Analyst Sees ‘Bigger Test’ Ahead Binance to Remove 5 Spot Trading Pairs Including GAS/TRY and HBAR/BNB on November 20 Micron Technology (MU) Stock Is Trending After Hours: Here's Why
Paytaca: Backend Systems Attacked but User Funds and Private Keys Unaffected, Warns Against Interacting with Suspicious Orders
‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors
Analysis: Bitcoin's 12% Weekly Drop and Break Below 200-Week Moving Average — All Three Similar Historical Cases Rose Three Months Later
Can Colette Kress Fill Jensen Huang’s Shoes? Nvidia Posts $116 Billion Quarter, but Analyst Sees ‘Bigger Test’ Ahead